Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events
Item 8.01Other Events
On June 6, 2017, Acorda Therapeutics, Inc. (the Company) issued a
press release announcing that it is presenting new data from
clinical and preclinical studies of tozadenant at the 2017
International Congress of Parkinsons Disease and Movement
Disorders (MDS), being held in Vancouver, British Columbia from
June 4-8, 2017. The Company is developing tozadenant as a daily
maintenance therapy to reduce OFF time for people with Parkinsons
taking an oral carbidopa / levodopa regimen. OFF refers to the
re-emergence of Parkinsons symptoms. The Company expects results
from an ongoing tozadenant Phase 3 clinical trial in the first
quarter of 2018. In addition, the Company initiated an
open-label, long-term safety study in the second quarter of 2017.
A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference into
this Item.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated June 6, 2017 |
About Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine.